fig5

The impact of rituximab prophylaxis on hepatocellular carcinoma recurrence after living donor liver transplantation

Figure 5. Overall survival (A) and recurrence (B) rates following LT in reference to rituximab administration in patients with HCC within the MC. HCC: Hepatocellular carcinoma; MC: Milan criteria; LT: liver transplantation.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/